A specific microRNA profile as predictive biomarker for systemic treatment in patients with metastatic colorectal cancer

Dennis Poel\textsuperscript{1,2} \textsuperscript{a} | Elske C. Gootjes\textsuperscript{1,2} | Lotte Bakkerus\textsuperscript{1,2} | Wim Trypsteen\textsuperscript{3} | Henk Dekker\textsuperscript{1} | Hans J. van der Vliet\textsuperscript{1} | Nicole C. T. van Grieken\textsuperscript{4} | Cornelis Verhoef\textsuperscript{5} | Tineke E. Buffart\textsuperscript{1,6} | Henk M. W. Verheul\textsuperscript{1,2} \textsuperscript{b}

1Department of Medical Oncology, Cancer Center Amsterdam, Amsterdam UMC, VU Universiteit Medical Center Amsterdam, Amsterdam, the Netherlands
2Department of Medical Oncology, Radboud University Medical Center, Nijmegen, the Netherlands
3Department of Internal Medicine and Pediatrics, Faculty of Medicine and Health Sciences, HIV Cure Research Center, Ghent University and Ghent University Hospital, Ghent, Belgium
4Department of Pathology, Cancer Center Amsterdam, Amsterdam UMC, VU Universiteit Medical Center Amsterdam, Amsterdam, the Netherlands
5Division of Surgical Oncology, Department of Surgery, Erasmus MC Cancer Institute, Rotterdam, the Netherlands
6Department of Gastrointestinal Oncology, Antoni van Leeuwenhoek, Amsterdam, the Netherlands

Abstract

Background: Palliative systemic therapy is currently standard of care for patients with extensive metastatic colorectal cancer (mCRC). A biomarker predicting chemotherapy benefit which prevents toxicity from ineffective treatment is urgently needed. Therefore, a previously developed tissue-derived microRNA profile to predict clinical benefit from chemotherapy was evaluated in tissue biopsies and serum from patients with mCRC.

Methods: Samples were prospectively collected from patients (N = 132) who were treated with capecitabine or 5-FU/LV with oxaliplatin ± bevacizumab. Response evaluation was performed according to RECIST 1.1 after three or four cycles, respectively. Baseline tissue and serum miRNAs expression levels of miR-17-5p, miR-20a-5p, miR-30a-5p, miR-92a-3p, miR-92b-3p, and miR-98-5p were quantified with RT-qPCR and droplet digital PCR, respectively. Combined predictive performance of selected variables was tested using logistic regression analysis.

Results: From 132 patients, 81 fresh frozen tissue biopsies from metastases and 93 serum samples were available. Based on expression levels of miRNAs in tissue, progressive disease could be predicted with an AUC of 0.85 (95% CI:0.72-0.91) and response could be predicted with an AUC of 0.70 (95% CI:0.56-0.80). This did not outperform clinical parameters alone (respectively \( p = .14 \) and \( p = .27 \)). Expression levels of miR-92a-3p and miR-98-5p in serum significantly improved the predictive value of clinical parameters for response to chemotherapy (AUC 0.74, 95% CI:0.64-0.84, \( p = .003 \)) in this cohort.

Conclusions: The additive predictive value to clinical parameters of the tissue-derived six miRNA profile for clinical benefit could not be validated in patients with mCRC treated with first-line systemic therapy. Although miR-92a-3p and miR-98-5p
1 | INTRODUCTION

MicroRNAs (miRNAs) are small noncoding RNAs that have an impact on many important biological processes by regulation of protein expression levels. In addition, miRNAs have favorable biomarker characteristics as they are easy to detect and resistant to degradation. Prior studies showed that tissue miRNAs are differentially expressed between normal and tumor tissue and between tumor subtypes. Furthermore, it has been observed that miRNAs from tumor cells are secreted into the circulation and can be detected in blood plasma and serum.1,2

Since it is possible to reliably detect miRNAs in human blood specimens, interest has shifted toward using miRNAs as a liquid biomarker. Tumor specific miRNAs may be released into the blood circulation through active secretion in exosomes or through passive secretion by cell death.3 Patients with high tumor load are expected to have high levels of tumor specific circulating miRNAs (ci-miRNAs). Previous studies have shown significant correlations between ci-miRNAs and tumor stage and between paired tissue and serum miRNA expression levels.4,5 These ci-miRNAs could function as a minimally invasive predictive biomarker for disease monitoring upon treatment.

Among cancer types, colorectal cancer (CRC) ranks in the top 3 for incidence and mortality worldwide.6,7 Approximately half of all patients diagnosed with CRC will have metastasis at diagnosis or develop them during the course of their disease.8 For patients with extensive metastatic disease, no treatment with curative intent is available. Standard of care for these patients is palliative systemic treatment that usually consists of 5-FU-based combination chemotherapy with oxaliplatin and/or irinotecan, anti-VEGF targeted therapy, and anti-EGFR antibodies. Overall survival with these modern regimens is an estimated 30 months.9,10 Currently, only for the use of anti-EGFR therapy a biomarker of response is available and it is recommended to exclude RAS and BRAF mutant tumors and right-sided primary tumors from anti-EGFR therapy.11,12 Since approximately 10%–20% of the patients do not benefit from first-line chemotherapy and will have progressive disease at first evaluation, there is a strong clinical need for a predictive biomarker.9,10,13,14

Previously, a model to predict response to palliative systemic treatment in patients with mCRC based on primary tumor expression of miRNAs and clinicopathological factors was developed. Six miRNAs (miR-17-5p, miR-20a-5p, miR-30a-5p, miR-92a-3p, miR-92b-3p and miR-98-5p) combined with four clinical parameters (the use of adjuvant chemotherapy after resection of the primary tumor, age, tumor differentiation, and type of systemic treatment, ie, oxaliplatin or irinotecan based) were predictive for clinical benefit with an AUC of 0.78.15 Furthermore, expression profiles of primary CRC tissues and metastatic lesions are highly comparable.16

Three of these miRNAs (miR-17-5p, miR-20a-5p, and miR-92a-3p) belong to the miR-17-92 cluster, also known as oncomir-1. miRNAs from this cluster are involved in tumor angiogenesis, treatment resistance, and CRC progression.17-20 The other miRNAs, miR-30a-5p, miR-92b-3p, and miR-98-5p are involved in proliferation of CRC cells.21-23 In addition, high expression of miR-92b-3p has previously been related to a prolonged progression-free survival in patients with mCRC treated with combined FOLFOX and bevacizumab.24 The current study aimed to prospectively validate the predictive value of clinical benefit from systemic treatment of the previously identified miRNA signature in a cohort of patients with extensive mCRC, starting first-line palliative systemic therapy.

2 | MATERIAL AND METHODS

2.1 | Tissue and serum samples

In total 132 consecutive patients enrolled in a clinical trial (the ORCHESTRA trial) between May 2013 and February 2017 were included for miRNA analysis. This trial is a randomized multicenter clinical trial for patients with multiorgan colorectal cancer metastases comparing the combination of chemotherapy and maximal tumor debulking vs chemotherapy alone (clinicaltrials.gov Identifier: NCT01792934).25 Of all patients, tissue samples and serum biopsies were prospectively collected as part of the translational study program.

Written informed consent was obtained from all patients included in this trial.26-28 At baseline, one to four fresh frozen 14-18 G needle biopsies were obtained (ultrasound or CT guided) from a metastatic lesion or from the primary tumor (endoscopically). The biopsy specimen was transferred to
a storage tin and snap frozen in liquid nitrogen and subsequently stored at −80°C.

Serum samples were collected in a BD vacutainer® tube, incubated upright for 1 hour and centrifuged at 1500 × g for 10 minutes at room temperature. Samples were aliquoted and stored at −80°C until RNA isolation. Specimens were collected prior to the start of systemic therapy.

Clinical parameters were documented and included age, gender, primary tumor sidedness (left or right), number of organs involved in metastatic disease, primary tumor in situ (yes or no), number of metastatic lesions (<5, 5-10, >10 or diffuse disease), differentiation (well/moderately, poor), prior (neo-) adjuvant chemotherapy (yes or no), CEA (elevated > 5 ng/µL, normal), LDH (elevated > 250 ng/µL, or normal).

All patients were treated with 5-FU/LV or capecitabine and oxaliplatin (46-hour continuous infusion of 5-FU/LV and oxaliplatin in a biweekly schedule (FOLFOX) or oxaliplatin IV followed by 14 days of oral capecitabine in a 3-week cycle (CAPOX)) ± bevacizumab at physician discretion. After three cycles of CAPOX(B) or four cycles of FOLFOX(B) a CT scan of thorax and abdomen was performed. Follow-up scans were performed at least every 3 months and evaluated according to RECIST v 1.1.

2.2 | RNA extraction

2.2.1 | Tissue

Dissection of fresh frozen biopsies was performed at approximately −25°C in a cryotome. Biopsies were enriched for tumor cells by macro dissection. Twenty micrometer sections were cut and snap frozen in liquid nitrogen and stored at −80°C until RNA extraction. Multiple 5 µmol/L sections were stained with hematoxylin and eosin (H&E) to confirm the presence of tumor cells across the biopsy. As stromal infiltration is a characteristic for worse prognosis, stromal percentage was included into tumor purity estimation.

The percentage of tumor field was defined as the sum of the percentage of tumor cells and the percentage of stromal cells. Samples were included if the percentage of tumor field was ≥ 30% as scored by a pathologist. RNA was isolated using the AllPrep® DNA/RNA/miRNA Universal Kit (Qiagen) according to the manufacturers protocol, eluted in 30-µL nuclease free water and quantified using a Nanodrop 2000 (Thermo Scientific).

2.2.2 | Serum

Serum RNA was extracted using the miRNeasy Serum/Plasma advanced Kit (Qiagen, former Exiqon). During RNA extraction a DNase step was included using the RNase-Free DNase Set (Qiagen) according to the manufacturers protocol.

2.3 | Hemolytic index

The hemolytic index (HI) of serum samples was measured using the automated Roche Modular Cobas 8000 platform according to the instructions of the manufacturer. Serum samples with a HI ≥ 10 were excluded for further analysis, since blood cells contain a lot of miRNAs and significant correlations between the HI and expression of certain ci-miRNAs was demonstrated before.

2.4 | miRNA quantification

2.4.1 | Tissue

miRNAs miR-16-5p, miR-17-5p, miR-20a-5p, miR-30a-5p, miR-92a-3p, miR-92b-3p, and miR-98-5p were quantified with reverse transcription quantitative PCR (RT-qPCR) and analyzed as previously described. The chemicals from Exiqon were replaced with the chemicals from Qiagen as Exiqon merged with Qiagen, using the miRCURY LNA RT kit for cDNA synthesis and the miRCURY LNA miRNA PCR assays together with miRCURY LNA SYBR® Green for miRNA quantification (Qiagen). Cq values were normalized with miR-16-5p as reported previously.

2.4.2 | Serum

cDNA synthesis was performed with the miRCURY LNA RT kit (Qiagen) using 3-µL-extracted RNA. Serum RNA quality was assessed by measuring synthetic miRNA spike-in of cel-miR-39-3p with RT-qPCR as described above using cel-miR-39-3p miRCURY LNA miRNA PCR assay (Qiagen). Samples were selected for droplet digital PCR (ddPCR) analysis if the raw Cq value was ≤ 30. cDNA was diluted 1:40 for ddPCR. Each ddPCR reaction consisted of 9.9-µL diluted cDNA, 11 µL of QX200 EvaGreen ddPCR Supermix (Bio-Rad, Veenendaal, The Netherlands), and 1.1-µL optimal concentration miRCURY LNA miRNA PCR assay. The optimal PCR assay volume was experimentally assessed for each assay using 1.0-µL, 0.5-µL, and if necessary 0.25-µL assay diluted in nuclease free H2O (Figure S1A). A gradient (52°C-62°C) ddPCR was performed for each assay to define the optimal annealing temperature (Figure S1B). Similar PCR assays were used as described in the section tissue miRNA quantification.
Twenty-microliter ddPCR reaction mix and subsequently 70 µL QX200™ droplet generation oil for EvaGreen (Bio-Rad) was loaded on a DG8™ Cartridge for QX200™/QX100™ droplet generator. Droplets were generated in a QX200™ droplet generator and a total of 40 µL was loaded in a ddPCR™ 96-Well-PCR plate (Bio-Rad). Each plate included a non-template control (NTC) and positive control for each PCR assay with H₂O and RNA from cancer cell lines as described previously.15 The PCR reaction was performed in a Thermal cycler (Bio-Rad) with a three-step protocol; (a) Enzyme activation: 5 minutes at 95°C, (b) PCR: 30 seconds at 95°C and 1 minute at primer specific annealing temperature repeated 40 times, (c) droplet stabilization: 5 minutes 4°C, 5 minutes 95°C, and at 4°C until droplet reading. Droplets were quantified in a Droplet Reader QX200™ (Bio-Rad) and the number of formed droplets was obtained using QuantaSoft software (Bio-Rad). If less than 10 000 droplets were formed, the PCR reaction for that particular sample was repeated. Threshold estimation to define positive and negative droplets together with absolute miRNA quantification was performed using the R-package “ddpcRquant” designed by Trypsteen and colleagues.35 The standard “ddpcRquant” package was designed for single plate analysis. Because the number of samples in this study exceeded the number wells of a single 96-well plate, the script was adapted to analyze multiple plates for the same assay. The final miRNA concentration in copies per µL cDNA was log₂ transformed and normalized for technical variation with log₂ transformed cel-miR-39-3p levels as described previously.31,33

2.5 | Statistical analysis

Predicting response after three to four cycles of chemotherapy was tested for two scenarios (a) clinical benefit (CB) defined as complete response (CR), partial response (PR), and stable disease (SD) together vs progressive disease (PD) and (b) CR or PR vs SD or PD. The models for response prediction were formulated using the combined miRNA expression and clinicopathological data collected from the current cohort (FF cohort). New prediction models were formed for different clinical endpoints with multivariate logistic regression analysis using Akaike’s information criterion (AIC)-based backward selection for selection of the best model. For the new prediction models the clinical parameter “type of systemic treatment” was excluded because all patients in the current FF cohort received the same systemic treatment. Performance of the models was evaluated by comparing AUCs of paired ROC curves (clinicopathological factors vs added value of the miRNA expression to these factors) as described before.15

As the prediction coefficients of the miRNAs from the models in the previous study (original FFPE cohort) are based on its miRNA expression levels, the miRNA expression levels in the FF cohort were compared with the expression levels in the original FFPE cohort.15 Because the FF cohort consisted only of patients with stage IV disease, and the original FFPE cohort consisted of patients with stage I to IV disease, the miRNA expression data from the original FFPE cohort were grouped in stage I-III and IV disease. Two comparisons were performed: (a) miRNA expression levels between stage I-III and IV in the original FFPE cohort and (b) miRNA expression between stage IV in the original FFPE cohort and stage IV in the FF cohort. The Welch’s two sample t test or two-sample t test were used for these comparisons.

Baseline characteristics from the patients in the FF cohort were compared to the baseline characteristics from the patients in the original FFPE cohort,15 as well as for the patients from the serum and tissue cohorts in the FF cohort. Fisher’s exact two-sided test, Pearson two-sided Chi-Square test or an unpaired t test were used to test significance in baseline characteristics between the different cohorts. P values < .05 were considered statistically significant. Log₂ normalized expression data were used to correlate serum vs tissue miRNA expression data. Unsupervised cluster analysis was performed with log₂ transformed normalized serum and tissue miRNA expression levels using ward.D2 clustering and Manhattan distance. Statistical analysis was performed using the R-package “CompareGroups” using R studio (version 1.1.423) with R software (version 3.5.0) downloaded from Bioconductor.36-38

3 | RESULTS

From May 2013 to March 2017, 132 patients with mCRC were included in the trial and available for analysis. From 29 patients no baseline tissue biopsy was available and from 12 patients, no baseline serum sample was available, leaving a total of 103 tissue samples (fresh frozen cohort) and 120 serum biopsies. Both serum and tumor biopsies were available in 95 patients.

From the available tissue samples, 22 were excluded due to a tumor field percentage < 30%, leaving a tissue cohort of 81 samples for further analyses. From 120 available serum samples, 24 were excluded due to a hemolytic index > 10, two were excluded because the hemolytic index was not assessable and one was excluded because of poor RNA quality (Figure 1), leaving a serum cohort of 93 samples. From 58 patients, miRNA expression could be quantified with good quality from both serum and tumor sample.

No significant differences were observed between the clinicopathological characteristics from the tissue cohort (N = 81) and the serum cohort (N = 93) (Table S1). Tumor
field percentage ranged from 30% to 100% with a median of 100% and a mean of 86% (Figure 2A). Of the included samples in the tissue cohort 53 (65%) were from liver metastases. Biopsies were collected from eight different organs (Figure 2B). Unsupervised cluster analysis of log2 transformed, miR-16-5p normalized, tissue miRNA expression data revealed two specific clusters. These clusters were not related to tumor field percentage (categorized in 30%-50%, 51%-80% and 81%-100%), location of the primary tumor (left- vs right-sided colon vs rectum), tumor-site biopsy (liver vs other) (Figure 2C).

In the serum cohort, raw Cq values of cel-miR-39-3p quantified with RT-qPCR ranged from 26 to 30 with a median of 28,38 (Figure 3A). Unsupervised cluster analysis of log2, cel-miR-39-3p normalized, serum miRNA expression data showed that cluster membership was not correlated to the location of the primary tumor, hemolytic index, or primary tumor location. In serum, high miRNA expression was observed for miR-92a-3p, miR-20a-5p, and miR-17-5p, whereas low expression was observed for miR-30a-5p, miR-92b-3p, and miR-98-5p (Figure 3B).
3.1 Prediction of treatment benefit

3.1.1 Tissue

In the tissue cohort five patients (6.17%) showed PD, 39 (48.1%) had SD, and 37 (45.7%) had PR after three or four cycles of chemotherapy (Table 1). The miRNA expression levels from the fresh frozen cohort combined with the age, tumor differentiation, use of adjuvant chemotherapy after primary resection, and type of palliative systemic therapy revealed low predictive value for treatment response in contrast to the previously developed model. Here, using the previously developed predictive model for CR and PR vs PD that included miR-92a-3p, miR-92b-3p, and the three clinicopathological covariates as variables, resulted in an AUC of 0.60, 95% CI, 0.35-0.85. Using the predictive model for CR and PR vs SD that included miR-17-5p, miR-92a-3p, miR-92b-3p, miR-98-5p, and differentiation grade of the primary tumor as variables, resulted in an AUC of 0.51, 95% CI, 0.37-0.64.\(^{15}\)

When performing a new backward selection starting with all nine variables and using AIC for model selection, the best predictive model contained expression levels of miR-17-5p, miR-92b-3p, and miR-98-5p only. Prediction of clinical benefit vs progressive disease at first evaluation by measured expression levels of these three miRNAs revealed a model with an AUC of 0.85 (95% CI: 0.72-0.91) (Figure 4A). The AUC of this model is higher compared to the AUC of the model with the parameters age, tumor differentiation, and prior use of adjuvant chemotherapy alone (AUC: 0.74, 95% CI, 0.56-0.92), but did not reach statistical significance (\(P = .14\)). The calculated predicted probabilities from the model are visualized in Figure 4B. For PD the predicted probabilities ranged between 0.04 and 0.53 with a median of 0.16 and for CR, PR and SD the predicted probabilities ranged between < 0.01 and 0.30 with a median of 0.16 (Figure 4B). Addition of miRNA expression levels to the clinicopathological covariates did not significantly improve the performance of the model to discriminate between patients with objective response (CR and PR) (\(n = 37\)) vs SD and PD (\(n = 44\)), (AUC: 0.67, 95% CI:0.55-0.79 vs AUC: 0.70, 95% CI:0.56-0.80 with miRNAs, \(P = .27\)) (Figure 4C), with a wide range of predicted probabilities (Figure 4D). For objective response the predicted probabilities ranged between 0.17 and 0.81 with a median of 0.47 and for SD and PD this ranged between 0.25 and 0.91 with a median of 0.58 (Figure 4D).

3.1.2 Serum

In the serum cohort, logistic regression analysis could not be performed because only three (3.2%) patients showed...
### TABLE 1 Comparison of the patient cohort used to compute the initial response prediction models (original FFPE cohort) vs the cohort used for this study (FF cohort)

|                                      | Prior cohort FFPE | FF cohort | P value |
|--------------------------------------|------------------|-----------|---------|
|                                      | N = 81           | N = 81    |         |
| **Gender**                           |                  |           |         |
| Female                               | 30 (37.0%)       | 28 (34.6%)| .870    |
| Male                                 | 51 (63.0%)       | 53 (65.4%)|         |
| **Age at diagnosis (median - range)**| 61 (37 - 81)     | 64 (28 - 81)| .129  |
| **Primary tumor location:**          |                  |           | .064    |
| Rectal                               | 20 (24.7%)       | 34 (42.0%)|         |
| Left sided                           | 30 (37.0%)       | 22 (27.2%)|         |
| Right sided                          | 31 (38.3%)       | 25 (30.9%)|         |
| **Stage**                            |                  |           | <.001   |
| I                                    | 1 (1.20%)        | 0 (0.00%) |         |
| II                                   | 13 (16.0%)       | 0 (0.00%) |         |
| III                                  | 12 (14.8%)       | 0 (0.00%) |         |
| IV                                   | 54 (66.7%)       | 81 (100%) |         |
| Unknown                              | 1 (1.20%)        | 0 (0.00%) |         |
| **Differentiation**                  |                  |           | .943    |
| Well/moderately differentiated       | 54 (66.7%)       | 54 (66.7%)|         |
| Poorly differentiated                | 15 (18.5%)       | 16 (19.8%)|         |
| Other                                | 0 (0.00%)        | 1 (1.23%) |         |
| Unknown                              | 12 (14.8%)       | 10 (12.3%)|         |
| **Prior adjuvant therapy**           |                  |           | .072    |
| Yes                                  | 7 (8.60%)        | 16 (19.8%)|         |
| No                                   | 74 (91.4%)       | 65 (80.2%)|         |
| **Liver metastases only**            |                  |           | <.001   |
| No                                   | 57 (70.4%)       | 81 (100%) |         |
| Yes                                  | 24 (29.6%)       | 0 (0.00%) |         |
| **LDH (cut-off 250 ng/µL)**          |                  |           | <.001   |
| Elevated                             | 55 (67.9%)       | 18 (22.2%)|         |
| Normal                               | 23 (28.4%)       | 56 (69.1%)|         |
| Unknown                              | 3 (3.70%)        | 7 (8.64%) |         |
| **CEA (cut-off 5 ng/µL)**            |                  |           | .643    |
| Elevated                             | 61 (75.3%)       | 55 (67.9%)|         |
| Normal                               | 17 (21.0%)       | 22 (27.2%)|         |
| Unknown                              | 3 (3.70%)        | 4 (4.94%) |         |
| **First-line treatment scheme**      |                  |           | <.001   |
| 5-FU monotherapy                     | 14 (17.3%)       | 0 (0.00%) |         |
| Oxaliplatin-based regimen            | 57 (70.4%)       | 81 (100%) |         |
| Irinotecan-based regimen             | 10 (12.3%)       | 0 (0.00%) |         |
| **Use of first-line Bevacizumab**    |                  |           | <.001   |
| No                                   | 51 (63.0%)       | 21 (25.9%)|         |
| Yes                                  | 30 (37.0%)       | 60 (74.1%)|         |
| **Best response to first-line treatment** |           |           | .025    |
| Complete response (CR)               | 2 (2.5%)         | 0 (0.00%) |         |

(Continues)
PD after three to four cycles of chemotherapy. When separating the study cohort in objective response vs SD and PD after three to four cycles of chemotherapy, a model with miR-92a-3p and miR-98-5p expression combined with previous adjuvant chemotherapy and tumor differentiation showed a significant better performance compared to the model with clinicopathological factors alone (AUC 0.74, 95%CI 0.64-0.84 vs AUC 0.67, 95%CI 0.56-0.78; P = .003) (Figure 5A). The calculated predicted probabilities are visualized in Figure 5B which ranged between 0.08 and 0.88 with a median of 0.42 for CR and PR (n = 46) vs 0.15 and 0.90 with a median of 0.59 for SD and PD (n = 47) (Figure 5B). From 58 patients, tissue and serum expression data were available. There was no correlation between tissue and serum expression of these six miRNAs (R = −0.11; P = .42) (Figure 5C).

3.2 | Comparison with original formalin-fixed paraffin-embedded (FFPE) cohort

Baseline characteristics of current FF cohort and the original FFPE cohort are shown in Table 1. There are significant differences in tumor stage (P < .001), with the current FF cohort including only patients with extrahepatic disease (stage IV) at diagnosis vs all stages at diagnosis in our original cohort. In the current FF cohort, a lower percentage of elevated LDH (P < .001) was observed and baseline tissue biopsies were from different locations (metastasis vs primary tumor) (P < .001). Systemic treatment schedules differed significantly for both chemotherapy (P < .001) and use of bevacizumab (P < .001). Also, response to therapy was significant different (P = .03) Table 1.

No differences were observed between miRNA expression in stage I-III and IV in the original FFPE cohort. All six miRNAs were significantly higher expressed in the current FF cohort compared to the original FFPE cohort ((P = .03; miR-92a-3p) and P < .01; miR-17-5p, miR-20a-5p, miR-30a-5p, miR-92b-3p, miR-98-5p) (Figure 6).

4 | DISCUSSION

In this prospective study we aimed to validate the predictive value of a previously identified miRNA profile combined with clinicopathological factors in predicting clinical benefit from first-line palliative systemic therapy in advanced mCRC.15 The same miRNA profile was quantified in serum specimens to test its predictive value as a liquid biomarker for clinical benefit to systemic treatment.

The predictive value of the tissue-derived six miRNA profile combined with the clinicopathological factors could not be validated in patients with mCRC starting with first-line systemic therapy. Compared to the cohort previously used for identification of the putative predictive profile, the clinical parameters of the currently analyzed FF cohort differed significantly with the most important difference being that this cohort consisted of only patients with stage IV disease. Studies have shown that expression levels of specific miRNAs differ between clinical tumor stages.39,40 Although, for miR-17, miR-20a, miR-30a, and miR-92a previous studies have shown no significant relation between miRNA expression and stage.20,41,42 miR-92b expression has not been related to stage before and Zhu et al found lower levels of miR-98 expression in patients with stage III-IV disease compared to patients with stage I-II disease.43 Since there was no significant difference in miRNA expression between patients with stage I-III (32%) vs stage IV (66.7%) disease in the previous cohort (see Table 1), we considered it worthwhile testing this signature in a cohort consisting of only patients with stage IV disease, who are starting first-line palliative systemic therapy.

Additionally, in the original study cohort, patients were treated with different chemotherapeutic agents, that is, 5-FU monotherapy, 5-FU with oxaliplatin-based regimens or 5-FU with irinotecan-based regimens, which was also an important covariate in the prediction model. In the current FF cohort, all patients received 5-FU with oxaliplatin-based chemotherapy and therefore this covariate consisted of one factor.
All six miRNAs were significantly higher expressed in the current FF cohort compared to the original FFPE cohort. Besides differences in patient characteristics, this could also be the result of methodological differences in RNA extraction and quantification, due to updated kits available from Qiagen (after Exiqon merged with Qiagen, the assays from Exiqon were updated by Qiagen to exhibit improved performance as stated in digital correspondence with Qiagen). In particular, the relatively low expressed miRNAs miR-17-5p, miR-30a-5p, miR-92b-3p, and miR-98-5p were significantly higher expressed in the updated assays.

Furthermore, the biopsy specimens in this cohort consisted of FF tissue, mainly from metastatic lesions, whereas in the original FFPE cohort biopsies consisted of FFPE tissue samples, mainly from the primary tumor. Although studies have shown good correlations between miRNAs quantified in paired FF and FFPE samples independent of the employed methodology, this factor cannot be completely ruled out since an analysis of FF vs FFPE of paired samples using similar methods has not been performed for this study.

We previously demonstrated that miRNA profiles of primary tumor and metastases are similar, making the biopsy
site an unlikely explanation for differences in miRNA expression levels. The miRNAs selected for this study were based on next generation sequencing (NGS) results from FF tissue of 88 patients with advanced CRC as described previously by Neerincx et al. The initial clinical endpoint in that study was clinical benefit vs progressive disease defined as best response to first-line treatment using Response Evaluation Criteria in Solid Tumors (RECIST version 1.1). In the study presented here, the response was assessed at first evaluation after three to four cycles of systemic therapy. In this cohort, only five patients had progressive disease at first evaluation (6.8%). Although this is a low number for predictive modeling, the miRNAs and clinicopathological parameters selected for this study are based on two independent cohorts of a total of 169 patients. The patient cohort in the current study was used for further validation of the miRNAs and clinicopathological parameters. If these parameters were truly predictive for response to chemotherapy a clinically relevant model should identify these five patients as nonresponders.

Using other evaluation time points (ie, after six to eight cycles, progression-free survival 6 or 9 months) did not improve the predictive value either.
miRNA expression by tumor cells may affect serum levels. This depends on the balance between the expression levels of tumor cells and the endogenous production of normal (circulating blood) cells in the body. High miRNA expression and release by tumor cells and low endogenous production are ideal for an optimal predictive biomarker. Here, three of six miRNAs also originate from blood cells (miR-17-5p, miR-92a-3p, and miR-20a-5p) and therefore have high baseline serum expression levels. This was confirmed in the current study. Consequently, miRNAs released from tumors may be insufficient to significantly alter these high baseline levels. On the contrary, miR-30a-5p, miR-92b-3p, and miR-98-5p were proven to have low baseline serum expression levels, but are also expressed at low levels in CRC tissue. Again, these low miRNA levels released from tumors might be insufficient to allow detection (with current technology) of alterations in baseline serum expression levels.
CONFICT OF INTEREST
The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

AUTHOR CONTRIBUTIONS
Henk Verheul and Kees Verhoef were involved in principal investigator, conceptualization, investigation, funding acquisition, writing revisions and supervision. Dennis Poel, Elske Gootjes, Lotte Bakkerus, and Tineke Buffart were involved in conceptualization, formal analysis, investigation, methodology, project administration, writing original manuscript, statistical methods, data curation, and writing revisions. Dennis Poel was involved in visualization. Wim Trypsteen was involved in statistical analysis and methods. Nicole CT van Grieken and Hans J van der Vliet were involved in investigation. Henk Dekker was involved in methodology. All authors reviewed and edited the original article, and approved the final version.

DATA AVAILABILITY STATEMENT
Please contact the corresponding author for all data requested.

ORCID
Dennis Poel  https://orcid.org/0000-0002-4395-2824
Henk M. W. Verheul  https://orcid.org/0000-0001-5981-922X

REFERENCES
1. Chen XI, Ba YI, Ma L, et al. Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res. 2008;18(10):997-1006.
2. Mitchell PS, Parkin RK, Kroh EM, et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci USA. 2008;105(30):10513-10518.
3. Schwarzenbach H, Nishida N, Calin GA, Pantel K. Clinical relevance of circulating cell-free microRNAs in cancer. Nat Rev Clin Oncol. 2014;11(3):145-156.
4. Hur K, Toiyama Y, Okugawa Y, et al. Circulating microRNA-203 predicts prognosis and metastasis in human colorectal cancer. Gut. 2017;66(4):654-665.
5. Xi Y, Nakajima G, Gavin E, et al. Systematic analysis of microRNA expression of RNA extracted from fresh frozen and formalin-fixed paraffin-embedded samples. RNA. 2007;13(10):1668-1674.
6. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394-424.
7. Cremolini C, Loupakis F, Antoniotti C, et al. FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study. Lancet Oncol. 2015;16(13):1306-1315.
8. Wolpin BM, Mayer RJ. Systemic treatment of colorectal cancer. Gastroenterology. 2008;134(5):1296-1310.
9. Venook AP, Niedzwiecki D, Lenz HJ, et al. Effect of first-line chemotherapy combined with cetuximab or bevacizumab on
overall survival in patients with KRAS wild-type advanced or metastatic colorectal cancer: a randomized clinical trial. *JAMA*. 2017;317(23):2392-2401.

10. Heinemann V, von Weikersthal LF, Decker T, et al. FOLFIRI plus cetuximab versus FOLFI RI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial. *Lancet Oncol*. 2014;15(10):1065-1075.

11. Stintzing S, Teijpar S, Gibbs P, Thiebach L, Lenz HJ. Understanding the role of primary tumour localisation in colorectal cancer treatment and outcomes. *Eur J Cancer*. 2017;84:69-80.

12. Douillard J-Y, Siena S, Cassidy J, et al. Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. *J Clin Oncol*. 2010;28(31):4697-4705.

13. Saltz LB, Dieras V, Tabernero J, et al. Bevacizumab plus oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. *J Clin Oncol*. 2008;26(12):2013-2019.

14. Hurwit H, Feihrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. *N Engl J Med*. 2004;350(23):2335-2342.

15. Neerincx M, Poel D, Sie DLS, et al. Combination of a six microRNA expression profile with four clinicopathological factors for response prediction of systemic treatment in patients with advanced colorectal cancer. *PloS One*. 2018;13(8):e0201809.

16. Neerincx M, Sie DLS, van de Wiel MA, et al. MiR expression profiles of paired primary colorectal cancer and metastases by next-generation sequencing. *Oncogenesis*. 2015;4:e170.

17. Chai H, Liu M, Tian R, Li X, Tang H. miR-20a targets BNIP2 and contributes chemotherapeutic resistance in colorectal adenocarcinoma SW480 and SW620 cell lines. *Acta Biochim Biophys Sin (Shanghai)*. 2011;43(3):217-225.

18. Ma Y, Zhang P, Wang F, et al. Elevated oncofoetal miR-17-5p expression regulates colorectal cancer progression by repressing its target gene P130. *Nat Commun*. 2012;3:1291.

19. van Beijnum JR, Giovannetti E, Poel D, Nowak-Sliwinska P, Griffioen AW. microRNAs: micro-managers of anticancer combination therapies. *J Surg Oncol*. 2017;28(31):4697-4705.

20. Yu GE, Tang J-Q, Tian M-L, et al. Prognostic values of the miR-21, miR-31, miR-143 and miR-145 is related to clinicopathologic features of colorectal adenocarcinoma. *J Cell Mol Med*. 2019;23(5):3151-3165.

21. Zheng YF, Luo J, Gan GL, Li W. Overexpression of microRNA-98 inhibits cell proliferation and promotes cell apoptosis via claudin-1 in human colorectal cancer. *J Cell Biochem*. 2019;120(4):6090-6105.

22. Kiss I, Mlčochová J, Součková K, et al. MicroRNAs as outcome predictors in patients with metastatic colorectal cancer treated with bevacizumab in combination with FOLFOX. *Oncol Lett*. 2017;14(1):743-750.

23. Zheng YF, Luo J, Gan GL, Li W. Overexpression of microRNA-98 inhibits cell proliferation and promotes cell apoptosis via claudin-1 in human colorectal cancer. *J Cell Biochem*. 2019;120(4):6090-6105.

24. Kiss I, Mlčochová J, Součková K, et al. MicroRNAs as outcome predictors in patients with metastatic colorectal cancer treated with bevacizumab in combination with FOLFOX. *Oncol Lett*. 2017;14(1):743-750.
44. Meng W, McElroy JP, Volinia S, et al. Comparison of microRNA deep sequencing of matched formalin-fixed paraffin-embedded and fresh frozen cancer tissues. *PLoS One*. 2013;8(5):e64393.

45. Leite KRM, Canavez JMS, Reis ST, et al. miRNA analysis of prostate cancer by quantitative real time PCR: comparison between formalin-fixed paraffin embedded and fresh-frozen tissue. *Urol Oncol*. 2011;29(5):533-537.

46. Zhu M, Zhang N, He S. Similarly up-regulated microRNA-106a in matched formalin-fixed paraffin-embedded and fresh frozen samples and the dynamic changes during gastric carcinogenesis and development. *Pathol Res Pract*. 2014;210(12):909-915.

47. Poel D, Rustenburg F, Sie D, et al. Expression of let-7i and miR-192 is associated with resistance to cisplatin-based chemoradiotherapy in patients with larynx and hypopharynx cancer. *Oral Oncol*. 2020;109:104851.

48. Freedman JE, Gerstein M, Mick E, et al. Diverse human extracellular RNAs are widely detected in human plasma. *Nat Commun*. 2016;7:11106.

49. Conev NV, Donev IS, Konsoulova-Kirova AA, Chervenkov TG, Kashlov JK, Ivanov KD. Serum expression levels of miR-17, miR-21, and miR-92 as potential biomarkers for recurrence after adjuvant chemotherapy in colon cancer patients. *Biosci Trends*. 2015;9(6):393-401.

50. Sun Y, Yang B, Lin M, Yu H, Chen H, Zhang Z. Identification of serum miR-30a-5p as a diagnostic and prognostic biomarker in colorectal cancer. *Cancer Biomark*. 2019;24(3):299-305.

51. Zhang J, Zhang K, Bi M, Jiao X, Zhang D, Dong Q. Circulating microRNA expressions in colorectal cancer as predictors of response to chemotherapy. *Anticancer Drugs*. 2014;25(3):346-352.

52. Cheng L, Sharples RA, Scicluna BJ, Hill AF. Exosomes provide a protective and enriched source of miRNA for biomarker profiling compared to intracellular and cell-free blood. *J Extracell Vesicles*. 2014;3(1):1-14.

**SUPPORTING INFORMATION**

Additional supporting information may be found online in the Supporting Information section.

---

**How to cite this article:** Poel D, Gootjes EC, Bakkerus L, et al. A specific microRNA profile as predictive biomarker for systemic treatment in patients with metastatic colorectal cancer. *Cancer Med*. 2020;9:7558–7571. [https://doi.org/10.1002/cam4.3371](https://doi.org/10.1002/cam4.3371)